Hormone replacement therapy and breast cancer. A review of current knowledge

Drug Safety

Volumn 15, Issue 5, 1996, Pages 360-370

  Bergkvist, Leif ^a,b   Persson, Ingemar ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; EARLY DIAGNOSIS; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0029907841     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615050-00006     Document Type: Review

References (79)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-62
3. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after estrogen and estrogen-progestin replacement. Br J Obstet Gynaecol 1992; 99: 821-8
4. Weiss NS, Ure CL, Ballarch JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-8
5. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987; 317: 1169-74
6. Naessén T, Persson I, Adami HO, et al. Hormone replacement therapy and the risk of first hip fracture: a prospective population based cohort study. Ann Intern Med 1990; 113: 95-103
7. Herrington LJ, Weiss NS. Postmenopausal unopposed estrogens: characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993; 3: 308-18
8. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147-51
9. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta analysis. Obstet Gynecol 1995; 85: 304-13
10. Mauvais-Jarvis P, Kuttenn F, Gompel A. Estradiol/progesterone interaction in normal and pathological breast cells. Ann NY Acad Sci 1986; 464: 152-67
11. Anderson TJ. Effects on breast tissue of exogenous oestrogens and progestogens. Acta Obstet Gynecol Scand Suppl 1986; 134: 9-13
12. Key TJA, Pike MC. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29-43
13. BCDSP. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9
14. Hoover R, Laman AG, Cole P, et al. Menopausal estrogens and breast cancer. N Engl J Med 1976; 295: 401-5
15. Casagrande J, Gerkins V, Henderson BE, et al. Brief communication: exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst 1976; 56: 839-41
16. Sartwell PE, Arthes FG, Tonascia JA. Exogenous hormones, reproductive history, and breast cancer. J Natl Cancer Inst 1977; 59: 1589-92
17. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9
18. Gambrell RD. The role or hormones in the etiology of breast and endometrial cancer. Acta Obstet Gynecol Scand Suppl 1979; 88: 73-81
19. Gambrell RD, Massey FM, Castaneda TA, et al. Estrogen therapy and breast cancer in postmenopausal women. J Am Geriatr Soc 1980; 28: 251-7
20. Jick H, Alexander MW, Watkins RN, et al. Replacement estrogens and breast cancer. Am J Epidemiol 1980; 112: 586-94
21. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243: 1635-9
22. Hoover R, Glass A, Finkle WD, et al. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst 1981; 67: 815-20
23. Brinton LA, Hoover RN, Szklo M, et al. Menopausal estrogen use and risk of breast cancer. Cancer 1981; 47: 2517-22
24. Lawson DH, Jick H, Hunter JR, et al. Exogenous estrogens and breast cancer. Am J Epidemiol 1981; 114: 710-3
25. Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67: 327-33
26. Thomas DB, Persing JP, Hutchinson WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast disease. J Natl Cancer Inst 1982; 69: 1017-25
27. Hulka BS, Chambles LE, Deubner DC, et al. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1982; 143: 638-44
28. Gambrell RD. Role of hormones in the etiology and prevention of endometrial and breast cancer. Acta Obstet Gynecol Scand Suppl 1982; 106: 37-46
29. Sherman B, Wallace R, Bean J. Estrogen use and breast cancer: interaction with body mass. Cancer 1983; 51: 1527-31
30. Vakil DV, Morgan RW, Halliday M. Exogenous estrogens and development of breast and endometrial cancer. Cancer Detect Prev 1983; 6: 415-24
31. Gambrell RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983; 62: 435-43
32. Kaufman DW, Miller DR, Rosenberg L, et al. Non-contraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252: 63-7
33. Hiatt RA, Bawol R, Friedman GD, et al. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 1984; 54: 139-44
34. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54: 825-32
35. La Vecchia C, Decarli A, Parazzini F, et al. Non-contraceptive oestrogens and the risk of breast cancer in women. Int J Cancer 1986; 38: 853-8
36. McDonald JA, Weiss NS, Daling JR, et al. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986; 7: 193-9
37. Nomura AMY, Kolonel LN, Hirohata T, et al. The association of replacement estrogens with breast cancer. Int J Cancer 1986; 37: 49-53
38. Buring JE, Hennekens CH, Lipnick RJ, et al. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol 1987; 125: 939-47
39. Wingo PA, Layde PM, Lee NC, et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209-15
40. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-35
41. Gambrell RD. Use of progestogen therapy. Am J Obstet Gynecol 1987; 156: 1304-13
42. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-8
43. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 1988; 148: 217-21
44. Bergkvist L, Adami H-O, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-7
45. Dupont WD, Page DL, Rogers LW, et al. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989; 63: 948-57
46. Mills PK, Beeson L, Phillips RL, et al. Prospective study of exogenous hormone use and breast cancer in seventh-day adventists. Cancer 1989; 64: 591-7
47. Colditz GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648-53
48. Kaufman DW, Palmer JR, deMouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134: 1375-85
49. Palmer JR, Rosenberg L, Clarke A, et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study. Am J Epidemiol 1991; 134: 1386-95
50. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow up from the Nurses' Health study. Cancer Causes Control 1992; 3: 433-9
51. Nachtigall MJ, Smilen SW, Nachtigall RD, et al. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80: 827-30
52. Yang CP, Daling JR, Band PR, et al. Non-contraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992; 3: 475-9
53. Persson I, Yuen J, Bergkvist L, et al. Combined oestrogen-progestogen replacement and breast cancer risk [letter]. Lancet 1992; 24: 1044
54. Randall EH, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992; 84: 1575-82
55. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol 1994; 139: 670-83
56. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491-500
57. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93
58. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-42
59. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995; 142: 788-95
60. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 1995; 6: 416-24
61. La Vecchia C, Negri E, Franchesi S, et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995; 72: 244-8
62. Gapstur SM, Potter JD, Drinkard C, et al. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 1995; 4: 313-8
63. Folsom AR, Mink PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study on postmenopausal women. Am J Public Health 1995; 85: 1128-32
64. La Vecchia C, Negri E, Franceschi S, et al. Non-contraceptive oestrogens and breast cancer: an update [letter]. In J Cancer 1992; 50: 161-2
65. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-71
66. Steinberg KK, Thacker SB, Smith J, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-90
67. Sillero-Arenas M, Delgado-Rodrigues M, Rodrigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286-94
68. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiological studies. Am J Obstet Gynecol 1993; 168: 1473-80
69. Persson I, Adami HO, Lindberg BS, et al. Practice and patterns of estrogen treatment in climacteric women in a Swedish population: a descriptive epidemiologic study. Part I. Acta Obstet Gynecol Scand 1983; 621: 289-96
70. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32
71. Campagnoli C, Briglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globuline serum levels. Gynecol Endocrinol 1993; 7: 251-8
72. Campagnoli C, Briglia N, Peris C, et al. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995; 9: 67-74
73. Capagnoli C, Briglia N, Lanza MG, et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum levels induced by conjugated estrogens in postmenopausal women. Preliminary report. Maturitas 1994; 19: 25-31
74. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biological prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11-7
75. Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestin replacement therapy. Am J Epidemiol 1989; 130: 221-8
76. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-6
77. Yuen J, Persson I, Bergkvist L, et al. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-users' effect. Cancer Causes Control 1993; 4: 369-74
78. Ettinger B, Friedman GD, Bush T, et al. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87: 6-12
79. Sturgeon SR, Schairer C, Brinton LA, et al. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995; 6: 227-31